• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development

    5/7/24 10:00:00 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TKNO alert in real time by email

    First-of-its-kind custom configurator – available today – gives scientists access to high quality, customizable buffers in small volumes for use in early-stage experiments, all with exceptionally short turnaround times

    Novel, multi-purpose AAV stabilizer solution increases capsid yield up to 50% while safeguarding product integrity across the AAV purification workflow

    HOLLISTER, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched the Company's first custom product configurator, Build-TekTM Solutions, specifically created to address the need for fast turnaround, high-quality buffers for use during early-stage therapy development. Teknova also announced the availability of the latest product in their proprietary AAV-TekTM Solutions product line – the AAV-Tek AAV Stabilizer – that substantially improves recovery and protects capsid integrity across the purification workflow.

    "I'm incredibly proud of our talented team and their unwavering focus on making solutions possible for our customers by addressing critical pain points during therapeutic development," said Stephen Gunstream, President and Chief Executive Officer. "With the launch of Build-Tek Solutions, we're now able to support research scientists with small volumes of multiple discrete buffer formulations that are made from high-quality raw materials and QC tested. Our custom configurator is easy to use, and by leveraging our modular manufacturing platform, products ship in a matter of days. Now scientists can focus on advancing science by getting reproducible, trusted results during their early-stage experiments instead of spending their time mixing buffers."

    Build-Tek Solutions is a fast turnaround, custom manufacturing platform that enables the customization of multiple, iterative buffers needed during early-stage research and design of experiments (DOE). By using an online custom configurator, scientists can order discrete buffer formulations combining a base buffer with optional salts and other additives in one-liter bottles, with no minimum order quantities. All buffers are made in an ISO 13485 certified facility using high-quality ingredients, and all raw materials and finished products are rigorously tested using USP-based quality control assays to ensure consistent quality and performance. Build-Tek makes buffers more efficiently and to higher quality standards than buffers made in the lab, enabling research scientists to eliminate a critical variable in their experiments and reduce the risk of inaccurate results and experimental failures.

    Build-Tek Solutions is available online today for orders of multiple iterations of Tris and phosphate buffers, along with a variety of optional salts and additives, with more base solutions and additives coming soon. Each one-liter bottle of base solution starts at $119; additional salts or additives are $15 each. Orders of up to 20 buffer formulations will ship within two days. Customers placing larger orders should contact Teknova directly for estimated shipping dates.

    "We're also expanding our support for gene therapy developers with the latest offering in our AAV-Tek Solutions proprietary product line, the AAV-Tek AAV Stabilizer," continued Mr. Gunstream. "This entire suite of product solutions is designed to target known pain points across the AAV workflow, and our new multi-purpose stabilizer is a powerhouse that significantly improves capsid yield – up to 50% – while protecting their functional integrity."

    Only from Teknova, the AAV-Tek AAV Stabilizer is for use during the filtration and capture steps of downstream processing and is designed to help achieve substantial recovery improvements while safeguarding the AAV product. Using a proprietary blend of poloxamer and sucrose, this multi-purpose, concentrated solution reduces turbidity and pressure during filtration, preventing aggregation, significantly increasing the recovery of functional capsids by up to 50%.

    The AAV-Tek AAV Stabilizer is a 100x concentrated solution that can be directly spiked into feed stock, buffers, and solutions, providing an easy-to-use and powerful safety factor for gene therapy developers to confidently progress across the AAV purification workflow, saving time and resources. It is ready to ship in 100 mL and 500 mL formats, and can be purchased via phone, email, or online. The 100 mL size is priced at $95 and the 500 mL size is priced at $245 per bottle.

    For more information about the Build-Tek Solutions Custom Configurator or to place an order, click here.

    For more information about the AAV-Tek AAV Stabilizer or to purchase it online, click here.

    ABOUT TEKNOVA  

    Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova's modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

    Investor Contact

    Matt Lowell

    Chief Financial Officer

    [email protected]

    +1 831-637-1100

    Media Contact

    Jennifer Henry  

    Senior Vice President, Marketing 

    [email protected]  

    +1 831-313-1259 



    Primary Logo

    Get the next $TKNO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TKNO

    DatePrice TargetRatingAnalyst
    7/22/2025$8.00Overweight
    Stephens
    2/10/2025$12.00Buy
    Craig Hallum
    3/12/2024Buy → Neutral
    BTIG Research
    7/20/2021Overweight
    Stephens
    7/20/2021$27.00Overweight
    Stephens & Co.
    7/20/2021Outperform
    Cowen & Co.
    7/20/2021$26.00Buy
    BTIG
    More analyst ratings

    $TKNO
    SEC Filings

    View All

    SEC Form 10-K filed by Alpha Teknova Inc.

    10-K - Alpha Teknova, Inc. (0001850902) (Filer)

    3/2/26 5:10:09 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alpha Teknova, Inc. (0001850902) (Filer)

    2/26/26 4:08:58 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Alpha Teknova Inc.

    10-Q - Alpha Teknova, Inc. (0001850902) (Filer)

    11/7/25 4:06:35 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidanceFourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior yearCompany provides 2026 revenue guidance of $42-44 million HOLLISTER, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2025. "After another successful year of disciplined execution against our strategic objectives,

    2/26/26 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market. Teknova will host a webcast and conference call on Thursday, February 26, 2026, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this l

    2/5/26 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports Third Quarter 2025 Financial Results

    Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2025. "We had a strong third quarter, our fifth consecutive quarter of year-over-year revenue growth, despite a very challenging funding backdrop for smal

    11/6/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Telegraph Hill Partners Iv, L.P. bought $14,999,999 worth of shares (12,096,773 units at $1.24) (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 9:13:16 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Lowell Matthew bought $49,999 worth of shares (40,322 units at $1.24), increasing direct ownership by 46% to 128,376 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:21 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Gunstream Stephen bought $100,000 worth of shares (80,645 units at $1.24), increasing direct ownership by 50% to 243,497 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:04 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens resumed coverage on Alpha Teknova with a new price target

    Stephens resumed coverage of Alpha Teknova with a rating of Overweight and set a new price target of $8.00

    7/22/25 7:51:11 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Craig Hallum initiated coverage on Alpha Teknova with a new price target

    Craig Hallum initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $12.00

    2/10/25 8:24:48 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova downgraded by BTIG Research

    BTIG Research downgraded Alpha Teknova from Buy to Neutral

    3/12/24 7:34:27 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Demski Martha J sold $40,512 worth of shares (8,000 units at $5.06), decreasing direct ownership by 40% to 12,000 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:59:45 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Vos Alexander

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Robertson Brett

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:06 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Financials

    Live finance-specific insights

    View All

    Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidanceFourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior yearCompany provides 2026 revenue guidance of $42-44 million HOLLISTER, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2025. "After another successful year of disciplined execution against our strategic objectives,

    2/26/26 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market. Teknova will host a webcast and conference call on Thursday, February 26, 2026, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this l

    2/5/26 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports Third Quarter 2025 Financial Results

    Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2025. "We had a strong third quarter, our fifth consecutive quarter of year-over-year revenue growth, despite a very challenging funding backdrop for smal

    11/6/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alpha Teknova Inc.

    SC 13D - Alpha Teknova, Inc. (0001850902) (Subject)

    7/19/24 4:11:25 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    2/14/24 4:06:12 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    10/6/23 4:10:58 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Leadership Updates

    Live Leadership Updates

    View All

    Teknova Announces New Board Member, Martha J. Demski

    HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Ms. Demski's appointment and Mr. McNamara's resignation will be ef

    8/16/23 8:00:00 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care